“Lemons for Obesity” Or Sour Grapes? A Key Dissent on Qnexa, With a Twist of Avandia
This article was originally published in RPM Report
NIH Cardiologist Michael Lauer takes a page out of the Cleveland Clinic playbook and rips an advisory committee for recommending approval of Vivus’ Qnexa for weight loss without demanding a pre-market outcomes study. But this is no Avandia: Cleveland Clinic cardiologist Michael Lincoff is on the other side of this debate.